Literature DB >> 17971663

Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion.

Alwyn Rapose1, Bilal Sarvat, Juan C Sarria.   

Abstract

Immune reconstitution inflammatory syndrome (IRIS) affects 30-43% of HIV and tuberculosis (TB) co-infected patients after starting highly active antiretroviral therapy (HAART). Pericarditis and pericardial effusion are rare manifestations of IRIS. We report a case of HIV-TB related IRIS that developed pericardial involvement. This complication resolved after treatment with ibuprofen. Antituberculous treatment and HAART were not interrupted. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17971663     DOI: 10.1159/000110494

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Immune restoration diseases reflect diverse immunopathological mechanisms.

Authors:  Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 2.  Management of individuals requiring antiretroviral therapy and TB treatment.

Authors:  Karen Cohen; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2010-01       Impact factor: 4.283

3.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08

Review 4.  Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.

Authors:  Steven E Lipshultz; Tracie L Miller; James D Wilkinson; Gwendolyn B Scott; Gabriel Somarriba; Thomas R Cochran; Stacy D Fisher
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

5.  Tuberculosis, human immunodeficiency virus, and the immune reconstitution inflammatory syndrome.

Authors:  A Rapose; S Karande
Journal:  J Postgrad Med       Date:  2017 Oct-Dec       Impact factor: 1.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.